Paper40586556
Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems.
Orszulak L and 14 others. Mol Pharm, 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems. Papers, record 40586556. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40586556
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hydrophilic and Amphiphilic Macromolecules as Modulators of the Physical Stability and Bioavailability of Piribedil: A Study on Binary Mixtures and Micellar Systems.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Piribedil | Major topic |
| Biological Availability | |
| Calorimetry, Differential Scanning | |
| Chemistry, Pharmaceutical | |
| Crystallization | |
| Drug Compounding | |
| Drug Liberation | |
| Drug Stability | |
| Hydrophobic and Hydrophilic Interactions | |
| Micelles | |
| Polyethylene Glycols | |
| Polymers | |
| Polyvinyls | |
| Solubility | |
| Spectroscopy, Fourier Transform Infrared | |
| X-Ray Diffraction |
Source PubMed
References71
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34273426 | Design, optimization and pharmacokinetic evaluation of Piribedil loaded solid lipid nanoparticles dispersed in nasal in situ gelling system for effective management of Parkinson's disease. | Int J Pharm | 2021 | https://conductscience.org/library/papers/34273426 | PubMed |
| 2 | 37635801 | Advances in the development of amorphous solid dispersions: The role of polymeric carriers. | Asian J Pharm Sci | 2023 | https://conductscience.org/library/papers/37635801 | PubMed |
| 3 | 32905026 | Pharmaceutical assessment of polyvinylpyrrolidone (PVP): As excipient from conventional to controlled delivery systems with a spotlight on COVID-19 inhibition. | J Drug Deliv Sci Technol | 2020 | https://conductscience.org/library/papers/32905026 | PubMed |
| 4 | 32414187 | The Use of Poly(N-vinyl pyrrolidone) in the Delivery of Drugs: A Review. | Polymers (Basel) | 2020 | https://conductscience.org/library/papers/32414187 | PubMed |
| 5 | 34637312 | Zeta Potential and Colloidal Stability Predictions for Inorganic Nanoparticle Dispersions: Effects of Experimental Conditions and Electrokinetic Models on the Interpretation of Results. | Langmuir | 2021 | https://conductscience.org/library/papers/34637312 | PubMed |
| 6 | 31961694 | Influence of Annealing in the Close Vicinity of Tg on the Reorganization within Dimers and Its Impact on the Crystallization Kinetics of Gemfibrozil. | Mol Pharm | 2020 | https://conductscience.org/library/papers/31961694 | PubMed |
| 7 | 31704609 | Assessing the viability of Soluplus® self-assembled nanocolloids for sustained delivery of highly hydrophobic lapatinib (anticancer agent): Optimisation and in-vitro characterisation. | Colloids Surf B Biointerfaces | 2020 | https://conductscience.org/library/papers/31704609 | PubMed |
| 8 | 22172603 | Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. | Eur J Pharm Sci | 2012 | https://conductscience.org/library/papers/22172603 | PubMed |
| 9 | 23383426 | Strategies to address low drug solubility in discovery and development. | Pharmacol Rev | 2013 | https://conductscience.org/library/papers/23383426 | PubMed |
| 10 | 27267583 | The role of the carrier in the formulation of pharmaceutical solid dispersions. Part II: amorphous carriers. | Expert Opin Drug Deliv | 2016 | https://conductscience.org/library/papers/27267583 | PubMed |
| 11 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 12 | 15793805 | Calorimetric investigation of the structural relaxation of amorphous materials: evaluating validity of the methodologies. | J Pharm Sci | 2005 | https://conductscience.org/library/papers/15793805 | PubMed |
| 13 | 30669484 | Micellisation Mechanism and Behaviour of Soluplus®⁻Furosemide Micelles: Preformulation Studies of an Oral Nanocarrier-Based System. | Pharmaceuticals (Basel) | 2019 | https://conductscience.org/library/papers/30669484 | PubMed |
| 14 | 39608423 | Inhibition of naproxen crystallization by polymers: The role of topology and chain length of polyvinylpyrrolidone macromolecules. | Eur J Pharm Biopharm | 2025 | https://conductscience.org/library/papers/39608423 | PubMed |
| 15 | 34952275 | Understanding the self-assembly of the polymeric drug solubilizer Soluplus®. | J Colloid Interface Sci | 2022 | https://conductscience.org/library/papers/34952275 | PubMed |
| 16 | 35269593 | Drug-Biopolymer Dispersions: Morphology- and Temperature- Dependent (Anti)Plasticizer Effect of the Drug and Component-Specific Johari-Goldstein Relaxations. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/35269593 | PubMed |
| 17 | 24046690 | 2-{4-[(1,3-Benzodioxol-5-yl)meth-yl]piperazin-1-yl}pyrimidine. | Acta Crystallogr Sect E Struct Rep Online | 2013 | https://conductscience.org/library/papers/24046690 | PubMed |
| 18 | 27344665 | Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. | CNS Drugs | 2016 | https://conductscience.org/library/papers/27344665 | PubMed |
| 19 | 20600305 | From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease. | Pharmacol Ther | 2010 | https://conductscience.org/library/papers/20600305 | PubMed |
| 20 | 23110256 | Drug release from nanomedicines: Selection of appropriate encapsulation and release methodology. | Drug Deliv Transl Res | 2012 | https://conductscience.org/library/papers/23110256 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41477341 | ROS-scavenging nanomaterials as emerging tools for bone tissue regeneration: A comprehensive review of recent progress. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/41477341 |
Source PubMed
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40586556
GET https://conductscience.org/api/papers/v1/40586556/references?page=2